Jessica Settineri, APRN
Adult Health · Orlando, FLNPI 1528766268
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $12,146 of the $14,476 with a category attached, or 83.9%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.8% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 523 payments — averaging $27.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Catalyst Pharmaceuticals, Inc.$3K
- UCB, Inc.$3K
- AbbVie$1K
- SK Life Science, Inc.$1K
- Pfizer$817
- Jazz Pharmaceuticals Inc.$622
- plus $5K from 23 others
What the payments were for
- Speaking & faculty fees$1,50010%
- Travel & lodging$8136%
- Food & beverage$12,14684%
- Education$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Catalyst Pharmaceuticals, Inc. | 33 | $3,156 |
| UCB, Inc. | 92 | $2,824 |
| AbbVie | 70 | $1,355 |
| SK Life Science, Inc. | 31 | $1,091 |
| Pfizer | 49 | $817 |
| Jazz Pharmaceuticals Inc. | 23 | $622 |
| Neurelis, Inc. | 33 | $594 |
| Livanova USA, Inc. | 23 | $509 |
| Acadia Pharmaceuticals Inc | 25 | $436 |
| Eisai Inc. | 22 | $415 |
| Otsuka America Pharmaceutical, Inc. | 10 | $292 |
| Biogen | 13 | $292 |
| Sumitomo Pharma America, Inc. | 15 | $291 |
| Teva Pharmaceuticals USA, Inc. | 13 | $289 |
| Lilly USA, LLC | 17 | $264 |
| Axsome Therapeutics, Inc. | 5 | $214 |
| Aucta Pharmaceuticals, Inc. | 14 | $159 |
| GE HealthCare | 6 | $149 |
| Telix Pharmaceuticals | 1 | $117 |
| Neurocrine Biosciences, Inc. | 5 | $116 |
| Amneal Pharmaceuticals LLC | 6 | $103 |
| Otter Pharmaceuticals, LLC | 4 | $103 |
| Impel Pharmaceuticals LLC | 3 | $62 |
| Impel Pharmaceuticals Inc. | 3 | $59 |
| Alnylam Pharmaceuticals Inc. | 2 | $38 |
| Lundbeck LLC | 1 | $34 |
| C2n Diagnostics, LLC | 2 | $30 |
| AstraZeneca | 1 | $29 |
| Almatica Pharma LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$14,476 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XcopriCenobamate | 40 | $50,353 |
| BriviactBrivaracetam | 37 | $50,194 |
| QuliptaAtogepant | 34 | $44,409 |
| UbrelvyUbrogepant | 32 | $43,659 |
| RexultiBrexpiprazole | 17 | $25,325 |
| Emgality PenGalcanezumab-Gnlm | 20 | $20,755 |
| FycompaPerampanel | 12 | $16,662 |
| Lamotrigine ErLamotrigine | 16 | $5,377 |
| Levetiracetam | 119 | $3,685 |
| Memantine Hcl | 120 | $2,726 |
| Lacosamide | 45 | $2,483 |
| Clonazepam | 44 | $1,577 |
| Lamotrigine | 69 | $1,104 |
| Primidone | 31 | $857 |
| Memantine Hcl ErMemantine Hcl | 19 | $820 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieQulipta, Ubrelvy | $1,355 | $88,06866 claims |
| SK Life Science, Inc.Xcopri | $1,091 | $50,35340 claims |
| UCB, Inc.Briviact | $2,824 | $50,19437 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $292 | $25,32517 claims |
| Eisai Inc.Fycompa | $415 | $16,66212 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.
Other adult health in Orlando
- Sita SwamyOrlando$49K
- Andreina NeallOrlando$16K
- Kristen KessingerOrlando$13K
- Angelo LewisOrlando$12K
- Patricia PagnottaMaitland$409K
- Carly KoelschSarasota$265K
- Norma SolisMiami$150K
- Ashley PontenbergWinter Park$136K
- Jeffrey HernandezMiami$122K
- Jamie JohnsonTampa$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.